Count | |
| 1 | |
| 3 | |
Dopamine Agonists/adverse effects/*pharmacokinetics/therapeutic use | 1 |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 5 | |
| 1 | |
| 12 | |
| 29 | |
| 1 | |
| 1 | |
| 3 | |
Dopamine Agonists/administration & dosage/pharmacology/*therapeutic use | 1 |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
Dopamine Agents/adverse effects/pharmacokinetics/*pharmacology | 1 |
| 3 | |
| 3 | |
| 1 | |
| 12 | |
| 3 | |
| 18 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
Receptors, Dopamine D2/agonists/antagonists & inhibitors/metabolism | 1 |
Receptors, Dopamine D2/agonists/antagonists & inhibitors/*metabolism | 2 |
Receptors, Dopamine D1/agonists/antagonists & inhibitors/*metabolism | 1 |
Dopamine Agonists/administration & dosage/*pharmacokinetics/*pharmacology | 1 |
| 1 | |
Dopamine Agonists/chemical synthesis/chemistry/metabolism/pharmacology | 1 |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 5 | |
| 9 | |
| 3 | |
| 1 | |
| 9 | |
| 4 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 3 | |
Dopamine/analogs & derivatives/*pharmacology/therapeutic use | 1 |
Dopamine Agents/administration & dosage/blood/*therapeutic use | 1 |
| 1 | |
| 5 | |
| 1 | |
| 2 | |
| 2 | |
| 4 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 3 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 5 | |
| 1 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |